GHO

News

Two top healthcare investors – UK-based GHO and CBC Group of Singapore – have announced a merger to create a massive player in the category.

News

Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.